AE Management With IO-TKI and IO-IO in RCC
Martin H. Voss, MD, outlines adverse events encountered with different IO-TKI and IO-IO combination regimens in RCC and discusses the importance of open communication with patients.
EP: 1.Overview of Advanced Non-Clear Cell Renal Cell Carcinoma
EP: 2.Current Treatment Options for Non-Clear Cell Renal Cell Carcinoma
EP: 3.IO-TKI Findings in nccRCC from KEYNOTE-B61
EP: 4.Duration of Therapy and Dosing Strategies in RCC
EP: 5.AE Management With IO-TKI and IO-IO in RCC
EP: 6.Multidisciplinary Strategies for Treating RCC
EP: 7.Meeting Unmet Needs for Patients With RCC
Video content above is prompted by the following question:
- What are the most significant adverse events seen with different IO-TKI and IO-IO combination regimens used in renal cell carcinoma (RCC)?
McGregor and Participants Discuss Impact of Drug Efficacy and Histology on nccRCC Care
October 17th 2024During a Case-Based Roundtable® event, Bradley McGregor, MD, moderated a discussion on prognosis and treatment approaches for a patient with stage IV papillary renal cell carcinoma.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Long-Term Data Prompt Shifting Approaches to Frontline RCC Therapy
October 8th 2024During a Case-Based Roundtable® event, Chandler Park, MD, moderated a discussion on how recent trial data and sites of metastasis affect treatment of favorable-risk metastatic clear cell renal cell carcinoma in the second article of a 2-part series.
Read More
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
GU Oncology Peers Explore Early Therapy Approaches in Low-Volume mRCC
September 19th 2024During a Case-Based Roundtable® event, Chandler Park, MD, moderated a discussion on treating patients with indolent or low-volume favorable-risk metastatic clear cell renal cell carcinoma in the first article of a 2-part series.
Read More
